NCT03139487View on ClinicalTrials.gov

A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism

PHASE2UnknownINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

August 7, 2017

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Cancer-associated ThrombosisEsophageal CancerStomach CancerHepatocellular CarcinomaPancreatic CancerDuodenal CancerEsophagogastric Junction CancerMalignant Gastrointestinal Stromal TumorAmpulla of Vater CancerBiliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)
Interventions
DRUG

Rivaroxaban

15 mg q12 hours for 3 weeks followed by 20mg q24 hours for 21 weeks

DRUG

Dalteparin

200 IU/kg q24 hours for 4 weeks followed by 150 IU/kg q24 hours for 20 weeks

DRUG

apixaban

10 mg q12 hours for 7days followed by 5mg q12 hours for 21 weeks

Trial Locations (1)

Unknown

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT03139487 - A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism | Biotech Hunter | Biotech Hunter